DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

EFC (I) Limited — Allotment of Securities

NSE 1 hr ago·1 Oct 2026, 12:26 pm

EFC (I)

EFC (I) Limited has informed stock exchanges that it has allotted 19,99,996 securities to investors. This allotment was made pursuant to a preferential issue approved by the company's board of directors during a meeting held on October 1, 2026. This process allows the company to raise capital directly from select investors without a public offer.

For investors, this development indicates that EFC (I) Limited is actively seeking to strengthen its financial position. The infusion of capital could be used for business expansion, debt repayment, or funding new projects. It signals the company's intent to grow its operations and improve its balance sheet.

Investors should monitor the company's future announcements to understand the specific purpose of these funds. Keeping an eye on the company's quarterly results will also help in assessing the impact of this capital infusion on its operational performance and overall financial health.